✦ LIBER ✦

Mesenchymal stromal cells for steroid-refractory acute graft-versus-host disease: a report of two cases

✍ Scribed by Joo Han Lim; Moon Hee Lee; Hyeon Gyu Yi; Chul Soo Kim; Jun Hyung Kim; Sun U. Song

Book ID: 107619056
Publisher: Carden Jennings Publishing
Year: 2010
Tongue: English
Weight: 120 KB
Volume: 92
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-010-0606-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mesenchymal stromal cell therapy for ste

Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study

✍ Richard Herrmann; Marian Sturm; Kathryn Shaw; Duncan Purtill; Julian Cooney; Mat 📂 Article 📅 2011 🏛 Carden Jennings Publishing 🌐 English ⚖ 227 KB

Infliximab treatment for steroid-refract

Infliximab treatment for steroid-refractory acute graft-versus-host disease after orthotopic liver transplantation: A case report

✍ Gaël Piton; Fabrice Larosa; Anne Minello; Marie-Claude Becker; Georges Mantion; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 1 views

Acute graft-versus-host disease (GVHD) following orthotopic liver transplantation is a rare but severe disease with a 75% death rate in adults. Various therapeutic strategies have been proposed for steroid-refractory GVHD, but there is still no consensus. Tumor necrosis factor-alpha is a key inflamm

Mycophenolate mofetil for the treatment

Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease

✍ Marta Krejci; Michael Doubek; Tomas Buchler; Yvona Brychtova; Jiri Vorlicek; Jir 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 82 KB

Intra-arterial methylprednisolone for th

Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease

✍ Laurie A. Milner; Michael W. Becker; Steven H. Bernstein; Lauren Bruckner; Jonat 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 681 KB

Staging System and chromosomal abnormalities determined by standard metaphase karyotype and/or fluorescence in situ hybridization (FISH). Treatment-induced adverse events were graded according to the National Cancer Institute common terminology criteria for adverse events (CTCAE) version 4.0. For r

Long term outcome of patients with stero

Long term outcome of patients with steroid-refractory acute intestinal graft versus host disease after treatment with pentostatin

✍ Stefan A. Klein; Gesine Bug; Sabine Mousset; Wolf-Karsten Hofmann; Dieter Hoelze 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB

Anti-LFA1 monoclonal antibody (25.3) for

Anti-LFA1 monoclonal antibody (25.3) for treatment of steroid-resistant grade III–IV acute graft-versus-host disease

✍ A. M. Stoppa; D. Maraninchi; D. Blaise; P. Viens; M. Hirn; D. Olive; J. Reiffers 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 537 KB

The in vivo efficacy of 25.3 monoclonal antibody (mAb) directed against human LFA1 molecule was assessed in ten patients with steroid-resistant grade III-IV acute graft-versus-host disease (AGVHD). These patients received non-T-cell-depleted allogeneic bone marrow transplantation for aplastic anemia